Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response

Table 1 Epigenetic writers and erasers approved for treatment or in clinical trial in cancer treatment

	Drug name	Commercial name	Class	Company	FDA-approved indication
Epigenetic Writers	Azacitidine	Vidaza	DNMTi	Celgene Corp	AML, CML, MDS
	5-Aza-2′-deoxycytadine	Dacogen	DNMTi	Eisai	AML, CML, MDS
	Tazemetostat	Tazverik	HMTi	Epizyme Inc	Epithelioid Sarcoma*
Epigenetic Erasers	Panobinostat	Farydak	HDACi	Novartis	Multiple Myeloma
	Vorinostat	Zolinza	pan-HDACi	Merk	CTCL
	Belinostat	Beleodaq	pan-HDACi	Spectrum pharmaceuticals	PTCL
	Romidepsin	Istodax	Class I HDACi	Celgene	CTCL/PTCL
	Chidamide	Epidaza	pan-HDACi	Chipscreen Biosciences	PTCL

Abbreviations: DNMTi: DNA methyltransferase inhibitors: HMTi: Histone methyltransferase inhibitor: HDACi: Histone deacteylase inhibitors: AML: Acute myeloid leukemia: CML: MDS: Myeloid dysplastic syndrome: CTCL: Cutaneous T-cell Lymphoma: PTCL: Peripheral T cell lymphoma. * approved in China only

ISSN: 1471-2172